Société Générale: A mild recession in the US would lead to a weaker dollar
According to ChainCatcher, citing Golden Ten Data, Société Générale strategist Kit Juckes pointed out that the U.S. economy faces the risk of slipping into a mild recession, which could trigger larger rate cuts and lead to a weaker dollar. He stated that slowing growth and high U.S. stock valuations could repeat the mild recession scenario of 2001. Juckes warned: "If concerns about inflation, economic growth, asset valuations, and market bubbles ultimately tip the balance and cause the economy to slide into recession, then the declines in both interest rates and the dollar could far exceed our expectations."
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
A key leap toward the internationalization of the Korean won: The Bank of Korea launches a trial run of its 24/7 international settlement system, with full deployment set for January next year.
The Bank of Korea officially launched the trial operation of the "BOK Won International Payment Network" on Monday local time.
Offshore oil and gas module equipment company VME (VME.US) aiming for Nasdaq listing, plans to raise up to 30 million USD
Offshore oil and gas process module and separation equipment company VME Companies has applied for an IPO on Nasdaq, aiming to raise up to $30 million, with Kingswood as the sole bookrunner.
Hypertension drug developer Retension (RTSN.US) applies for US listing, plans to raise $58 million.
U.S. hypertension drug developer Retension Pharmaceuticals filed documents with the SEC last Friday, planning to raise up to $58 million through an initial public offering (IPO).
Pfizer (PFE.US) overseas price increase gains to be shared with the U.S. government: "Most Favored Nation" contract revealed, over twenty transactions still confidential
According to reports, under a new contract with the U.S. Department of Health and Human Services, Pfizer will share higher overseas drug revenues with the United States.
